| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10899342 | Cancer Letters | 2016 | 11 Pages |
Abstract
Bone-marrow derived MSCs migrate to the tumor parenchyma and differentiate into pericytes, inducing tumor vasculogenesis after SBRT, and promoting tumor recurrence. MSC migration and maturation may be abrogated with AMD3100 and imatinib. This novel treatment strategy warrants clinical investigation.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Huan-Huan Wang, Yao-Li Cui, Nicholas G. Zaorsky, Jie Lan, Lei Deng, Xian-Liang Zeng, Zhi-Qiang Wu, Zhen Tao, Wen-Hao Guo, Qing-Xin Wang, Lu-Jun Zhao, Zhi-Yong Yuan, You Lu, Ping Wang, Mao-Bin Meng,